Inhibition of the NF-κB signaling pathway mediates the anti-inflammatory effects of petrosaspongiolide M

Biochemical Pharmacology

Volumn 65, Issue 5, 2003, Pages 887-895

  Posadas, Inmaculada ^a   Terencio, Maria Carmen ^a   Randazzo, Antonio ^b   Gomez Paloma, Luigi ^b   Payá, Miguel ^a   Alcaraz, Maria José ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Mouse air pouch; Mouse peritoneal macrophages; NF B; Petrosaspongiolide M; TNF ; Zymosan

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; NITRITE; PETROSASPONGIOLIDE M; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZYMOSAN; DNA; DRUG DERIVATIVE; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; MESSENGER RNA; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NOS2 PROTEIN, MOUSE; OLEANOLIC ACID; PROSTAGLANDIN SYNTHASE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; FEMALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL MODEL; CELL MOTION; DRUG ANTAGONISM; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL TRANSPORT; CELL MOVEMENT; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DNA; I-KAPPA B PROTEINS; ISOENZYMES; MACROPHAGES, PERITONEAL; MICE; MODELS, ANIMAL; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; OLEANOLIC ACID; PHOSPHORYLATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

EID: 0037332356     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01659-3     Document Type: Article

References (37)

1. Serhan C.N., Haeggström J.Z., Leslie C.C. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1996;1147-1158.
2. 2. Annu. Rev. Pharmacol. Toxicol. 39:1999;175-189.
3. 2-activating protein and by activation of phospholipase C and D. J. Biol. Chem. 276:2001;5467-5475.
4. Ueno N., Murakami M., Kudo I. Functional crosstalk between phospholipase D(2) and signaling phospholipase A(2)/cyclooxygenase-2-mediated prostaglandin biosynthetic pathways. FEBS Lett. 475:2000;242-246.
5. 2 and arthritis. Arthritis Rheum. 36:1993;190-198.
6. 2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. Am. J. Respir. Crit. Care Med. 155:1997;421-425.
7. 2 in concert with polymorphonuclear leukocytes. J. Biol. Chem. 269:1994;26331-26337.
8. 2 and platelet-activating factor on Mac-1 surface expression and exocytosis of gelatinase granules in human neutrophils: evidence for the 5-lipoxygenase-dependent mechanism. J. Immunol. 160:1998;5066-5072.
9. 2 inhibitor, on acute and chronic inflammation. J. Pharmacol. Exp. Ther. 289:1999;166-172.
10. Feldmann M., Maini R.N. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 38(Suppl 2):1999;3-7.
11. Karin M. The beginning of the end: IκB kinase (IKK) and NF-κB activation. J. Biol. Chem. 274:1999;27339-27342.
12. Abraham E. NF-κB activation. Crit. Care Med. 28:2000;N100-N104.
13. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107:2001;135-142.
14. 2 inhibitors from the new Caledonian marine sponge Petrosaspongia nigra. J. Nat. Prod. 61:1998;571-575.
15. Posadas I., Terencio M.C., Guillén I., Ferrándiz M.L., Coloma J., Payá M., Alcaraz M.J. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch. Pharmacol. 361:2000;98-106.
16. Pennanen N., Lapinjoki S., Palander A., Urtti A., Monkkonen J. Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion. Int. J. Immunopharmacol. 17:1995;475-480.
17. Misko T.P., Schilling R.J., Salvemini D., Moore W.M., Currie M.G. A fluorometric assay for the measurement of nitrite in biological samples. Anal. Biochem. 214:1993;11-16.
18. Moroney M.A., Alcaraz M.J., Forder R.A., Carey F., Hoult J.R.S. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. J. Pharm. Pharmacol. 40:1988;787-792.
19. López-Collazo E., Hortelano S., Rojas A., Boscá L. Triggering of peritoneal macrophages with IFN-α/β attenuates the expression of inducible nitric oxide synthase through a decrease in NF-κB activation. J. Immunol. 160:1998;2889-2895.
20. Castrillo A., Diaz-Guerra M.J., Hortelano S., Martin-Sanz P., Bosca L. Inhibition of IκB kinase and IκB phosphorylation by 15-deoxy-delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20:2000;1692-1698.
21. Chen Z., Hagler J., Palombella V.J., Melandri F., Scherer D., Ballard D., Maniatis T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev. 9:1995;1586-1597.
22. 2 regulation. J. Biol. Chem. 275:2000;20146-20156.
23. Drouet C., Shakhov A.N., Jongeneel C.V. Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J. Immunol. 147:1991;1694-1700.
24. Xie Q.W., Kashiwabara Y., Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269:1994;4705-4708.
25. Caivano M., Gorgoni B., Cohen P., Poli V. The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBPbeta ) and C/EBPdelta transcription factors. J. Biol. Chem. 276:2001;48693-48701.
26. Young S.H., Ye J., Frazer D.G., Shi X., Castranova V. Molecular mechanism of tumor necrosis factor-alpha production in. 1→3 -beta-glucan (zymosan)-activated macrophages J. Biol. Chem. 276:2001;20781-20787.
27. Bondeson J., Foxwell B., Brennan F., Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5668-5673.
28. Monks B.G., Martell B.A., Buras J.A., Fenton M.J. An upstream protein interacts with a distinct protein that binds to the cap site of the human interleukin 1 beta gene. Mol. Immunol. 31:1994;139-151.
29. Chan C.C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A.W., Forrest M.J., Gauthier J.Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill G.P., Ouellet M., Patrick D., Percival M.D., Perrier H., Prasit P., Rodger I. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290:1999;551-560.
30. Friedland J.S., Constantin D., Shaw T.C., Stylianou E. Regulation of interleukin-8 gene expression after phagocytosis of zymosan by human monocytic cells. J. Leukoc. Biol. 70:2001;447-454.
31. Bondeson J., Browne K.A., Brennan F.M., Foxwell B.M., Feldmann M. Selective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-κB independent. J. Immunol. 162:1999;2939-2945.
32. Imbert V., Rupec R.A., Livolsi A., Pahl H.L., Traenckner E.B., Mueller-Dieckmann C., Farahifar D., Rossi B., Auberger P., Baeuerle P.A., Peyron J.F. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α Cell. 86:1996;787-798.
33. Glaser K.B., Sung A., Bauer J., Weichman B.M. Regulation of eicosanoid biosynthesis in the macrophage. Involvement of protein tyrosine phosphorylation and modulation by selective protein tyrosine kinase inhibitors. Biochem. Pharmacol. 45:1993;711-721.
34. Nakano H., Shindo M., Sakon S., Nishinaka S., Mihara M., Yagita H., Okumura K. Differential regulation of IκB kinase alpha and beta by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3537-3542.
35. Soriente A., De Rosa M.M.C., Scettri A., Sodano G., Terencio M.C., Paya M., Alcaraz M.J. Manoalide. Curr. Med. Chem. 6:1999;415-431.
36. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 403:2000;103-108.
37. 2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J. Immunol. 165:2000;2790-2797.